Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus + mycophenolate mofetil + fluvastatin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of three medications used in transplant patients. Sirolimus (rapamycin) is an mTOR inhibitor immunosuppressant that prevents organ transplant rejection. Mycophenolate mofetil is an inosine monophosphate dehydrogenase inhibitor also used to prevent transplant rejection. Fluvastatin is a statin that lowers cholesterol levels. The combination may be used in renal transplant patients who require both immunosuppression and cholesterol management. Sirolimus and mycophenolate mofetil have complementary immunosuppressive properties, with sirolimus inhibiting mTOR and mycophenolate mofetil acting as an antiproliferative drug by inhibiting inosine monophosphate dehydrogenase.
- Brand names
- RapamuneCellCeptLescol
- Other names
- sirolimus + mycophenolat mofetil + fluvastatin-University Hospital Schleswig-Holstein-kidney transplant rejection-hyperlipidemia
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on sirolimus + mycophenolate mofetil + fluvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus + mycophenolate mofetil + fluvastatin.